|
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical research trials and Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes clinical trial. Participants frequently obtain the most expert healthcare available for their Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes  Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
For Condition: Diabetes Mellitus, Insulin-Dependent
Status: Completed
Sponsor(s): Procter & Gamble Pharmaceuticals ,
Synopsis: Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: - Age 18-65 - fasting C-peptide <0.3 ng/ml. - HbA1c <10% - Otherwise healthy
Total Enrollment:
Location and Contact Information:
Clinical Research Institute of Southern Oregon
Medforo, Oregon, 97504
United States
Radiant Research
Irvine, California, 92618
United States
Mercury Street Medical
Butte, Montana, 59701
United States
MedStar Clinical Research Center
Washington D.C., District of Columbia, 20003
United States
DGD Research Associates
San Antonio, Texas, 78229
United States
VA Hospital UCSD
San Diego, California, 92161
United States
University of Texas Health Science Center - Texas Diabetes Institute
San Antonio, Texas, 78207
United States
Diablo Clinical Research
Walnut Creek, California, 94598
United States
UNC Diabetes Care Center
Durham, North Carolina, 27713
United States
Springfield Diabetes and Endocrine Center
Springfield, Illinois, 62704
United States
Additional Information:
Study ID Numbers: 2003068;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071409
Other Diabetes Mellitus, Insulin-Dependent Studies:
1. Continuous Glucose Monitors for Children With Diabetes Mellitus
2. Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
3. Depression In Juvenile Diabetics
4. hOKT3gamma1 (Ala-ala) for the prevention of human islet allograft failure
5. Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Related Studies:
Other Diabetes Mellitus, Insulin-Dependent Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials
Safety and Efficacy of INGAP-Peptide in Patients with Type 1 Diabetes
|
|
|
|
|
|
|
|
